Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer

British Journal of Cancer

Volumn 99, Issue 6, 2008, Pages 858-861

  Schonnemann K R ^a   Jensen, H A ^a   Yilmaz, M ^c   Jensen, B V ^b   Larsen, O ^b   Pfeiffer, P ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Advanced gastric cancer; Capecitabine; Epirubicin; EXE; Oxaliplatin

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH ADENOCARCINOMA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EPIRUBICIN; ESOPHAGOGASTRIC JUNCTION; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 51449084893     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604569     Document Type: Article

References (24)

1. Al-Batran S, Hartmann J, Probst S, Hofheinz R, Stoehlmacher J, Schmalenberg H, Hollerbach S, Schuch G, Homann N, Jäger E (2006) ASCO Annual Meeting Proceedings Part I. J Clin Oncol Vol 24, No. 18S (June 20 Suppl): LBA4016
2. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488
3. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E (2004) Xelox/capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22(11): 2084-2091
4. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathé G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rythm modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050
5. Coleman MP, Gatta G, Verdecchia A, Estève J, Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani M, Berrino F, EUROCARE Working Group (2003) Eurocare-3 summery: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(Suppl 5): 128-149
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced oesophagogastric cancer. N Engl J Med 358: 36-46
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
8. Dupont J, Jensen HA, Jensen BV, Pfeiffer P (2006) Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. Acta Oncol 46: 330-335
9. Evans TR, Lofts Fj, Mansi JL, Glees JP, Dalgleish AG, Knight MJ (1996) A phase II study of continous infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73: 1260-1264
10. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H et al (1994) A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609-616
11. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R (1997) Randomized comparison between chemotherapy plus best surportive care with bestsurportive care in advanced gastric cancer. Ann Oncol 8: 163-168
12. Janunger KG, Hafström L, Nygren P, Glimelius B, SBU-group. Swedish Council of Technology Assessment in Health Care (2001) A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2/3: 309-326
13. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281
14. Murad AM, Santiago FE, Prtroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with flourouracil doxorubicin and methorexate in advanced gastic cancer. Cancer 72: 37-41
15. Neri B, Pantaleo P, Griommoni E, Grifoni R, Paoletti C, Rotella V, Pantalone D, Taddei A, Mercatelli A, Tonelli P (2007) Oxaliplatin, 5-fluorouracil and epirubicin as first line treatment in advanced gastic carcinoma: a phase II study. Br J Cancer 96(7): 1043-1046
16. Pfeiffer P, Hahn P, Jensen HA (2003) Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 42: 832-836
17. Pfeiffer P, Sorbye H, Ehrsson H, Fokstuen T, Mortensen JP, Baltesgard L, Tveit KM, Øgreid D, Starkhammar H, Wallin I, Qvortrup C, Glimelius B (2006) Short-time infusion of oxaliplatin in combination with capecitabine (Xelox30) as second line therapy in patients with advanced colorectal cancer after faliure to irinotecan and 5-fluorouracil. Ann Oncol 33: 70-74
18. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomized comparised of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus surportive care with surportive care alone in patients with nonresectable gastric cancer. Br J Cancer 71: 587-591
19. Raymond E, Faivre S, Coundray AM, Louvet C, Gespach C (2001) Preclinical studies of oxalilpatin in combination chemotherapy. Bull Cancer 88(Spec. No.): 26-34
20. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20: 1996-2004
21. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, V325 Study Group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997
22. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909
23. Waters JS, Norman A, Cuningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80: 269-272
24. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin and fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261-267